1
|
Alvarez I, Modolell A, Mayordomo JI, Janariz J, Centelles M, García JM, Puerto P, Diego C, Madroñal C, Burillo-R Andres MA. Biweekly nonpegylated liposomal doxorubicin (M) and docetaxel (T) as neoadjuvant treatment in patients with stage II-III breast cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.11049] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11049 Background: We have previously reported (ASCO 2006) the efficacy and toxicity of 4 courses of M (75mg/m2) and T (75mg/m2) with G-CSF support in a 21 day schedule as neoadjuvant treatment in patients with resectable breast cancer. Aim: To evaluate the clinical and pathological response rate (RR) and toxicity of biweekly M and T given prior to surgery in patients with breast cancer. Methods: Patients with histological confirmation of breast cancer (stage II-III and inflammatory), age >18 years, left ventricular ejection fraction > 45% and adequate bone marrow, renal and hepatic function were included in the study. Prior systemic therapy, radiotherapy or surgery for breast cancer were not allowed. The treatment was: M (60 mg/m2) and T (60mg/m2) each in 1 hour infusion, with subcutaneous G-CSF (5 mcg/kg) support on days 4–9. Courses were repeated every 14 days. Patients received 6 courses prior to surgery. Results: To date 45 patients have been enrolled; 20 who have completed therapy and underwent surgery (except for patients with progression) were included in this interim analysis. Median age: 48 years (38–63), ECOG PS 0: 90%, ECOG PS1: 10%, postmenopausal: 35%. Histology was infiltrating ductal carcinoma in 80%. Patients received a total of 110 courses (median 6, range 2–6). Efficacy: Of 19 evaluable patients, 4 achieved a clinical complete response (cCR) (21%), 12 partial response (cPR) (63%), 1 stable disease (cSD) (5%) and 2 progressive disease (cPD) (10%), resulting in a clinical response rate (cRR) of 84%. Surgery was performed in 17 (85%) patients, 4 (23%) of them had pathological complete response (pCR), 12 (70%) partial response (pPR), 1 (6%) stable disease (pSD), resulting in a pathological RR of 93%. Median time to progression and overall survival have not been reached. Toxicity: Hematological grade III/IV toxicities per patient were neutropenia (10%), febrile neutropenia (10%) and thrombocytopenia (5%). Non-hematological grade III/IV toxicities per patient were mucositis (10%), nausea/vomiting (10%) and epigastralgia (10%) Conclusions: Six courses of T and M every 14 days with G- CSF support as induction treatment in stage II and III breast cancer are active and well tolerated. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- I. Alvarez
- San Jorge Hospital, Huesca, Spain; Instituto de Oncología Corachan, Barcelona, Spain; Hospital Clínico, Zaragoza, Spain; Cruz Roja, Hospitalet, Spain; Sagrat Cor, Barcelona, Spain; Serosa, Palma de Mallorca, Spain; Hospital Infanta Cristina, Badajoz, Spain; Clínica Roger, Palma de Mallorca, Spain
| | - A. Modolell
- San Jorge Hospital, Huesca, Spain; Instituto de Oncología Corachan, Barcelona, Spain; Hospital Clínico, Zaragoza, Spain; Cruz Roja, Hospitalet, Spain; Sagrat Cor, Barcelona, Spain; Serosa, Palma de Mallorca, Spain; Hospital Infanta Cristina, Badajoz, Spain; Clínica Roger, Palma de Mallorca, Spain
| | - J. I. Mayordomo
- San Jorge Hospital, Huesca, Spain; Instituto de Oncología Corachan, Barcelona, Spain; Hospital Clínico, Zaragoza, Spain; Cruz Roja, Hospitalet, Spain; Sagrat Cor, Barcelona, Spain; Serosa, Palma de Mallorca, Spain; Hospital Infanta Cristina, Badajoz, Spain; Clínica Roger, Palma de Mallorca, Spain
| | - J. Janariz
- San Jorge Hospital, Huesca, Spain; Instituto de Oncología Corachan, Barcelona, Spain; Hospital Clínico, Zaragoza, Spain; Cruz Roja, Hospitalet, Spain; Sagrat Cor, Barcelona, Spain; Serosa, Palma de Mallorca, Spain; Hospital Infanta Cristina, Badajoz, Spain; Clínica Roger, Palma de Mallorca, Spain
| | - M. Centelles
- San Jorge Hospital, Huesca, Spain; Instituto de Oncología Corachan, Barcelona, Spain; Hospital Clínico, Zaragoza, Spain; Cruz Roja, Hospitalet, Spain; Sagrat Cor, Barcelona, Spain; Serosa, Palma de Mallorca, Spain; Hospital Infanta Cristina, Badajoz, Spain; Clínica Roger, Palma de Mallorca, Spain
| | - J. M. García
- San Jorge Hospital, Huesca, Spain; Instituto de Oncología Corachan, Barcelona, Spain; Hospital Clínico, Zaragoza, Spain; Cruz Roja, Hospitalet, Spain; Sagrat Cor, Barcelona, Spain; Serosa, Palma de Mallorca, Spain; Hospital Infanta Cristina, Badajoz, Spain; Clínica Roger, Palma de Mallorca, Spain
| | - P. Puerto
- San Jorge Hospital, Huesca, Spain; Instituto de Oncología Corachan, Barcelona, Spain; Hospital Clínico, Zaragoza, Spain; Cruz Roja, Hospitalet, Spain; Sagrat Cor, Barcelona, Spain; Serosa, Palma de Mallorca, Spain; Hospital Infanta Cristina, Badajoz, Spain; Clínica Roger, Palma de Mallorca, Spain
| | - C. Diego
- San Jorge Hospital, Huesca, Spain; Instituto de Oncología Corachan, Barcelona, Spain; Hospital Clínico, Zaragoza, Spain; Cruz Roja, Hospitalet, Spain; Sagrat Cor, Barcelona, Spain; Serosa, Palma de Mallorca, Spain; Hospital Infanta Cristina, Badajoz, Spain; Clínica Roger, Palma de Mallorca, Spain
| | - C. Madroñal
- San Jorge Hospital, Huesca, Spain; Instituto de Oncología Corachan, Barcelona, Spain; Hospital Clínico, Zaragoza, Spain; Cruz Roja, Hospitalet, Spain; Sagrat Cor, Barcelona, Spain; Serosa, Palma de Mallorca, Spain; Hospital Infanta Cristina, Badajoz, Spain; Clínica Roger, Palma de Mallorca, Spain
| | - M. A. Burillo-R Andres
- San Jorge Hospital, Huesca, Spain; Instituto de Oncología Corachan, Barcelona, Spain; Hospital Clínico, Zaragoza, Spain; Cruz Roja, Hospitalet, Spain; Sagrat Cor, Barcelona, Spain; Serosa, Palma de Mallorca, Spain; Hospital Infanta Cristina, Badajoz, Spain; Clínica Roger, Palma de Mallorca, Spain
| |
Collapse
|
2
|
Mayordomo JI, Madroñal C, Garcia-Lopez MJ, Burillo MA, Perez V, Janariz J, Murillo L, Andres R, Lara R, Lambea J, Alvarez Javier Sanz I. Safety analysis of docetaxel (T) and doxorubicin (A) followed by sequential capecitabine (X) as adjuvant chemotherapy of patients with node-positive operable breast cancer (BC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. I. Mayordomo
- Hosp Clinico Univ, Zaragoza, Spain; Inst de Oncologia Corachan, Barcelona, Spain; Hosp Nuestra Señora de Alarcos, Ciudad Real, Spain; Hosp Gen San Jorge, Huesca, Spain; Hosp de la Arritxaca, Murcia, Spain; Hosp de la Cruz Roja, Hospitalet (Barcelona), Spain; Hosp de Tudela, Tudela (Navarra), Spain
| | - C. Madroñal
- Hosp Clinico Univ, Zaragoza, Spain; Inst de Oncologia Corachan, Barcelona, Spain; Hosp Nuestra Señora de Alarcos, Ciudad Real, Spain; Hosp Gen San Jorge, Huesca, Spain; Hosp de la Arritxaca, Murcia, Spain; Hosp de la Cruz Roja, Hospitalet (Barcelona), Spain; Hosp de Tudela, Tudela (Navarra), Spain
| | - M. J. Garcia-Lopez
- Hosp Clinico Univ, Zaragoza, Spain; Inst de Oncologia Corachan, Barcelona, Spain; Hosp Nuestra Señora de Alarcos, Ciudad Real, Spain; Hosp Gen San Jorge, Huesca, Spain; Hosp de la Arritxaca, Murcia, Spain; Hosp de la Cruz Roja, Hospitalet (Barcelona), Spain; Hosp de Tudela, Tudela (Navarra), Spain
| | - M. A. Burillo
- Hosp Clinico Univ, Zaragoza, Spain; Inst de Oncologia Corachan, Barcelona, Spain; Hosp Nuestra Señora de Alarcos, Ciudad Real, Spain; Hosp Gen San Jorge, Huesca, Spain; Hosp de la Arritxaca, Murcia, Spain; Hosp de la Cruz Roja, Hospitalet (Barcelona), Spain; Hosp de Tudela, Tudela (Navarra), Spain
| | - V. Perez
- Hosp Clinico Univ, Zaragoza, Spain; Inst de Oncologia Corachan, Barcelona, Spain; Hosp Nuestra Señora de Alarcos, Ciudad Real, Spain; Hosp Gen San Jorge, Huesca, Spain; Hosp de la Arritxaca, Murcia, Spain; Hosp de la Cruz Roja, Hospitalet (Barcelona), Spain; Hosp de Tudela, Tudela (Navarra), Spain
| | - J. Janariz
- Hosp Clinico Univ, Zaragoza, Spain; Inst de Oncologia Corachan, Barcelona, Spain; Hosp Nuestra Señora de Alarcos, Ciudad Real, Spain; Hosp Gen San Jorge, Huesca, Spain; Hosp de la Arritxaca, Murcia, Spain; Hosp de la Cruz Roja, Hospitalet (Barcelona), Spain; Hosp de Tudela, Tudela (Navarra), Spain
| | - L. Murillo
- Hosp Clinico Univ, Zaragoza, Spain; Inst de Oncologia Corachan, Barcelona, Spain; Hosp Nuestra Señora de Alarcos, Ciudad Real, Spain; Hosp Gen San Jorge, Huesca, Spain; Hosp de la Arritxaca, Murcia, Spain; Hosp de la Cruz Roja, Hospitalet (Barcelona), Spain; Hosp de Tudela, Tudela (Navarra), Spain
| | - R. Andres
- Hosp Clinico Univ, Zaragoza, Spain; Inst de Oncologia Corachan, Barcelona, Spain; Hosp Nuestra Señora de Alarcos, Ciudad Real, Spain; Hosp Gen San Jorge, Huesca, Spain; Hosp de la Arritxaca, Murcia, Spain; Hosp de la Cruz Roja, Hospitalet (Barcelona), Spain; Hosp de Tudela, Tudela (Navarra), Spain
| | - R. Lara
- Hosp Clinico Univ, Zaragoza, Spain; Inst de Oncologia Corachan, Barcelona, Spain; Hosp Nuestra Señora de Alarcos, Ciudad Real, Spain; Hosp Gen San Jorge, Huesca, Spain; Hosp de la Arritxaca, Murcia, Spain; Hosp de la Cruz Roja, Hospitalet (Barcelona), Spain; Hosp de Tudela, Tudela (Navarra), Spain
| | - J. Lambea
- Hosp Clinico Univ, Zaragoza, Spain; Inst de Oncologia Corachan, Barcelona, Spain; Hosp Nuestra Señora de Alarcos, Ciudad Real, Spain; Hosp Gen San Jorge, Huesca, Spain; Hosp de la Arritxaca, Murcia, Spain; Hosp de la Cruz Roja, Hospitalet (Barcelona), Spain; Hosp de Tudela, Tudela (Navarra), Spain
| | - I. Alvarez Javier Sanz
- Hosp Clinico Univ, Zaragoza, Spain; Inst de Oncologia Corachan, Barcelona, Spain; Hosp Nuestra Señora de Alarcos, Ciudad Real, Spain; Hosp Gen San Jorge, Huesca, Spain; Hosp de la Arritxaca, Murcia, Spain; Hosp de la Cruz Roja, Hospitalet (Barcelona), Spain; Hosp de Tudela, Tudela (Navarra), Spain
| |
Collapse
|
3
|
Lara R, Mayordomo JI, Modolell A, Burillo M, Sanz J, Murillo L, Janariz J, Perez V, Andres R, Tres A. Feasibility of adjuvant chemotherapy with doxorubicin plus docetaxel followed by sequential capecitabine in patients with node positive breast cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. Lara
- Hospital Clinico Universitario, Zaragoza, Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Tudela, Tudela, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital de la Arritxaca, Murcia, Spain
| | - J. I. Mayordomo
- Hospital Clinico Universitario, Zaragoza, Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Tudela, Tudela, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital de la Arritxaca, Murcia, Spain
| | - A. Modolell
- Hospital Clinico Universitario, Zaragoza, Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Tudela, Tudela, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital de la Arritxaca, Murcia, Spain
| | - M. Burillo
- Hospital Clinico Universitario, Zaragoza, Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Tudela, Tudela, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital de la Arritxaca, Murcia, Spain
| | - J. Sanz
- Hospital Clinico Universitario, Zaragoza, Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Tudela, Tudela, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital de la Arritxaca, Murcia, Spain
| | - L. Murillo
- Hospital Clinico Universitario, Zaragoza, Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Tudela, Tudela, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital de la Arritxaca, Murcia, Spain
| | - J. Janariz
- Hospital Clinico Universitario, Zaragoza, Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Tudela, Tudela, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital de la Arritxaca, Murcia, Spain
| | - V. Perez
- Hospital Clinico Universitario, Zaragoza, Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Tudela, Tudela, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital de la Arritxaca, Murcia, Spain
| | - R. Andres
- Hospital Clinico Universitario, Zaragoza, Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Tudela, Tudela, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital de la Arritxaca, Murcia, Spain
| | - A. Tres
- Hospital Clinico Universitario, Zaragoza, Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Tudela, Tudela, Spain; Hospital de la Cruz Roja, Hospitalet (Barcelona), Spain; Hospital de la Arritxaca, Murcia, Spain
| |
Collapse
|
4
|
Llorca C, Mayordomo J, Adrover E, Alvarez I, Madroñal C, Burillo M, Sanz J, Lorenzo A, Palombo H, Janariz J. Activity and safety of biweekly docetaxel plus capecitabine as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Llorca
- Hospital de Elda, Elda (Alicante), Spain; Hospital Clinico Universitario, Zaragoza, Spain; Hospital General, Alicante, Spain; Hospital de Tudela, Tudela (Navarra), Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Puerto Real, Cadiz, Spain; Clinica del Remedio, Barcelona, Spain; Hospital de la Cruz Roja, Barcelona, Spain
| | - J. Mayordomo
- Hospital de Elda, Elda (Alicante), Spain; Hospital Clinico Universitario, Zaragoza, Spain; Hospital General, Alicante, Spain; Hospital de Tudela, Tudela (Navarra), Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Puerto Real, Cadiz, Spain; Clinica del Remedio, Barcelona, Spain; Hospital de la Cruz Roja, Barcelona, Spain
| | - E. Adrover
- Hospital de Elda, Elda (Alicante), Spain; Hospital Clinico Universitario, Zaragoza, Spain; Hospital General, Alicante, Spain; Hospital de Tudela, Tudela (Navarra), Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Puerto Real, Cadiz, Spain; Clinica del Remedio, Barcelona, Spain; Hospital de la Cruz Roja, Barcelona, Spain
| | - I. Alvarez
- Hospital de Elda, Elda (Alicante), Spain; Hospital Clinico Universitario, Zaragoza, Spain; Hospital General, Alicante, Spain; Hospital de Tudela, Tudela (Navarra), Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Puerto Real, Cadiz, Spain; Clinica del Remedio, Barcelona, Spain; Hospital de la Cruz Roja, Barcelona, Spain
| | - C. Madroñal
- Hospital de Elda, Elda (Alicante), Spain; Hospital Clinico Universitario, Zaragoza, Spain; Hospital General, Alicante, Spain; Hospital de Tudela, Tudela (Navarra), Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Puerto Real, Cadiz, Spain; Clinica del Remedio, Barcelona, Spain; Hospital de la Cruz Roja, Barcelona, Spain
| | - M. Burillo
- Hospital de Elda, Elda (Alicante), Spain; Hospital Clinico Universitario, Zaragoza, Spain; Hospital General, Alicante, Spain; Hospital de Tudela, Tudela (Navarra), Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Puerto Real, Cadiz, Spain; Clinica del Remedio, Barcelona, Spain; Hospital de la Cruz Roja, Barcelona, Spain
| | - J. Sanz
- Hospital de Elda, Elda (Alicante), Spain; Hospital Clinico Universitario, Zaragoza, Spain; Hospital General, Alicante, Spain; Hospital de Tudela, Tudela (Navarra), Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Puerto Real, Cadiz, Spain; Clinica del Remedio, Barcelona, Spain; Hospital de la Cruz Roja, Barcelona, Spain
| | - A. Lorenzo
- Hospital de Elda, Elda (Alicante), Spain; Hospital Clinico Universitario, Zaragoza, Spain; Hospital General, Alicante, Spain; Hospital de Tudela, Tudela (Navarra), Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Puerto Real, Cadiz, Spain; Clinica del Remedio, Barcelona, Spain; Hospital de la Cruz Roja, Barcelona, Spain
| | - H. Palombo
- Hospital de Elda, Elda (Alicante), Spain; Hospital Clinico Universitario, Zaragoza, Spain; Hospital General, Alicante, Spain; Hospital de Tudela, Tudela (Navarra), Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Puerto Real, Cadiz, Spain; Clinica del Remedio, Barcelona, Spain; Hospital de la Cruz Roja, Barcelona, Spain
| | - J. Janariz
- Hospital de Elda, Elda (Alicante), Spain; Hospital Clinico Universitario, Zaragoza, Spain; Hospital General, Alicante, Spain; Hospital de Tudela, Tudela (Navarra), Spain; Instituto de Oncologia Corachan, Barcelona, Spain; Hospital San Jorge, Huesca, Spain; Hospital de Puerto Real, Cadiz, Spain; Clinica del Remedio, Barcelona, Spain; Hospital de la Cruz Roja, Barcelona, Spain
| |
Collapse
|